Related Experiment Videos
Proliferating cell nuclear antigen in benign breast diseases
M R Cardillo1, G W Stamp, M Pignatelli
1Department of Experimental Medicine, University La Sapienza, Rome, Italy.
European Journal of Gynaecological Oncology
|January 1, 1995
Summary
Proliferating cell nuclear antigen (PCNA) expression increases with breast disease severity. High PCNA levels are found in invasive breast carcinoma, indicating its role as an early proliferation indicator.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Proliferating cell nuclear antigen (PCNA) is a marker of cellular proliferation.
- Understanding PCNA expression in various breast lesions is crucial for diagnosis and prognosis.
Purpose of the Study:
- To investigate the correlation between PCNA expression and different types of breast lesions.
- To evaluate PCNA as an early indicator of cellular proliferation in breast disease.
Main Methods:
- Immunohistochemistry was used to examine PCNA expression in 95 formalin-fixed breast surgical specimens.
- Specimens included benign breast disease, atypical hyperplasia, in situ carcinoma, and invasive carcinoma.
- PCNA expression was quantified using a scoring system (PCNA score I, II, and III).
Main Results:
- PCNA nuclear staining was observed in 42% of benign breast disease, 75% of atypical hyperplasia/in situ carcinoma, and 92% of invasive breast carcinoma.
- High PCNA levels (score III) were detected in 50% of atypical hyperplasia/in situ carcinoma and 54% of invasive breast carcinoma.
- PCNA expression varied across benign conditions, with cysts, sclerosing adenosis, adenosis, and epitheliosis showing different levels.
Conclusions:
- PCNA expression significantly correlates with the progression of breast lesions from benign to malignant.
- PCNA serves as a valuable early indicator of cellular proliferation in breast disease.
- Immunohistochemical analysis of PCNA aids in differentiating breast lesion types and assessing proliferative activity.